Thus, the inhibition of GRX in gefitinib-resistant NSCLC cells, carrying the EGFR mutation, enhances the efficacy of gefitinib by promoting apoptosis and cell cycle arrest through the modulation of the EGFR/FoxM1 signaling pathway [81]. Here, GLRX is linked to non-small cell lung carcinoma.